Browsing Tag
CSL Vifor
5 posts
CSL (ASX: CSL) names new CEO. Can 5% profit growth sustain its rally?
CSL shares have recovered sharply from their June lows as investors anticipate an earnings turnaround. The appointment of Deborah Waterhouse brings fresh leadership, but flat revenue guidance and persistent weakness at CSL Vifor leave an important question about how much recovery is already reflected in the share price.
CSL commits US$355m to lixudebart as rare kidney pipeline gains strategic weight
CSL is committing US$355 million upfront and funding a multi-indication clinical programme around Alentis Therapeutics’ lixudebart, giving the Australian biopharma group a potential new nephrology anchor as its existing Vifor portfolio faces material revenue headwinds.
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients
Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus.
American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint
American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID…